Skip to main content
Midas Edge

ANGIODYNAMICS INC

For the period ended May 31, 2026. Filed Jul 14, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2026 · Filed Jul 14, 2026

ANGO$12.12+3.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

(b) Exhibits

EXHIBITS

Incorporated by Reference
Exhibit NumberDescription of ExhibitsFormExhibitFiling Date
2.2Asset Purchase Agreement dated as of June 8, 2023 by and between AngioDynamics, Inc. and Merit Medical Systems, Inc.8-K2.4June 14, 2023
3.1.1Amended and Restated Certificate of Incorporation.10-Q3.1October 7, 2005
3.1.2Certificate of Amendment to the Amended and Restated Certificate of Incorporation of AngioDynamics, Inc.10-K3.1.2August 10, 2015
3.2Second Amended and Restated By-Laws, effective October 16, 2015.8-K10.1October 21, 2015
10.1Credit Agreement, dated as of May 28, 2025, by and among AngioDynamics, Inc., RITA Medical Systems, LLC, the lenders party thereto, JPMorgan Chase Bank, N.A., individually and as administrative agent, issuing bank and swingline lender.8-K10.1May 28, 2025
10.1.2Transition and Retirement Agreement, dated as of February 3, 2026, by and between AngioDynamics, Inc. and James C. Clemmer8-K10.1February 3, 2026
10.1.3AngioDynamics, Inc. 2004 Stock and Incentive Award Plan (as amended).DEF 14AAugust 30, 2018
10.1.6AngioDynamics 2017 Total Shareholder Return Performance Unit Agreement Program.10-Q10.1September 29, 2017
10.1.7AngioDynamics 2018 Total Shareholder Return Performance Unit Agreement Program.10-K10.1.7July 23, 2018
10.1.8AngioDynamics 2019 Total Shareholder Return Performance Unit Agreement Program.10-Q10.1.8January 8, 2020
10.1.9AngioDynamics, Inc. 2020 Stock and Incentive Award Plan (as amended)DEF 14ASeptember 28, 2023
10.2AngioDynamics, Inc. Employee Stock Purchase Plan (as amended).DEF 14ASeptember 3, 2020
10.2.1Form of AngioDynamics Retention Incentive Letter Agreement8-K10.2February 3, 2026
10.3Form of Non-Statutory Stock Option Agreement pursuant to the AngioDynamics, Inc. Stock and Incentive Award Plan.10-Q10.1October 12, 2004
10.3.1Form of Non-Statutory Stock Option Agreement pursuant to the AngioDynamics, Inc. Stock and Incentive Award Plan.10-K10.3.1July 23, 2018
10.4.3Form of 2016 Performance Share Award Agreement pursuant to the AngioDynamics, Inc. 2004 Stock and Incentive Award Plan.10-Q10.2October 5, 2016
10.4.4Form of 2017 Performance Share Award Agreement pursuant to the AngioDynamics, Inc. 2004 Stock and Incentive Award Plan.10-Q10.2September 29, 2017
10.4.5Form of 2018 Performance Share Award Agreement pursuant to the AngioDynamics, Inc. 2004 Stock and Incentive Award Plan.10-K10.4.5July 23, 2018
10.4.6Form of 2020 Performance Share Award Agreement pursuant to the AngioDynamics, Inc. 2004 Stock and Incentive Award Plan10-Q10.4.6January 8, 2021
10.4.7Form of Performance Share Award Agreement pursuant to the 2020 Stock and Incentive Award Plan10-Q10.4.7September 30, 2021
10.5Form of Restricted Stock Award Agreement pursuant to the AngioDynamics, Inc. 2004 Stock and Incentive Award Plan.8-K10.3May 12, 2005
10.6Rita Medical Systems, Inc. 1994 Incentive Stock Plan.S-110.2May 3, 2000
10.7Horizon Medical Products, Inc. 1998 Stock Incentive Plan.S-110.11February 13, 1998
10.8Rita Medical Systems, Inc. 2000 Stock Plan.S-1/A10.3June 14, 2000
Exhibit NumberDescription of ExhibitsFormExhibitFiling Date
10.9Rita Medical Systems, Inc. 2000 Directors’ Stock Plan, as amended on June 8, 2005.S-899.2July 8, 2005
10.10Rita Medical Systems, Inc. 2005 Stock and Incentive Plan.S-899.1July 8, 2005
10.11Form of Indemnification Agreement of AngioDynamics, Inc.8-K10.1May 12, 2006
10.11.1Employment Agreement, dated April 1, 2016, between AngioDynamics, Inc. and James C. Clemmer.8-K10.1April 6, 2016
10.12Change in Control Agreement, dated April 1, 2016, between AngioDynamics, Inc. and James C. Clemmer.8-K10.2April 6, 2016
10.12.2Form of Severance Agreement of AngioDynamics, Inc.10-K10.12.2August 10, 2020
10.13Form of Change in Control Agreement.10-K/A10.13January 12, 2015
10.14Performance Share Award Agreement, with a grant date of April 4, 2016, between AngioDynamics, Inc. and James C. Clemmer.8-K10.3April 6, 2016
10.15AngioDynamics, Inc. Total Shareholder Return Performance Share Award Program - Performance Period Ending July 2019.8-K10.4April 6, 2016
10.16Stock Option Award Agreement, with a grant date of April 4, 2016, between AngioDynamics, Inc. and James C. Clemmer.8-K10.5April 6, 2016
10.17Restricted Stock Unit Award Agreement, with a grant date of April 4, 2016, between AngioDynamics, Inc. and James C. Clemmer.8-K10.6April 6, 2016
10.18Separation Agreement and General Release, dated April 22, 2016, between AngioDynamics, Inc. and Joseph M. DeVivo.8-K10.1April 27, 2016
10.19Amended and Restated Change in Control Agreement, by and between AngioDynamics, Inc. and James C. Clemmer.8-K10.1February 3, 2021
10.2Form of Amended and Restated Change in Control Agreement with AngioDynamics, Inc.8-K10.2February 3, 2021
10.21*Settlement and License Agreement, dated March 31, 2024, by and among Becton, Dickinson and Company, C.R. Bard, Inc., Bard Peripheral Vascular, Inc. and AngioDynamics Inc.10-K10.21July 25, 2024
14Code of Conduct
19Insider Trading Policy10-K19July 18, 2025
21Subsidiaries
23Consent of Deloitte & Touche LLP, an independent registered public accounting firm.
31.1Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
97Clawback Policy10-K97July 18, 2025
101.INSXBRL Instance Document
101.SCHXBRL Schema Document
101.CALXBRL Calculation Linkbase Documents
101.DEFXBRL Taxonomy Extension Definition Linkbase Document
101.LABXBRL Labels Linkbase Documents
101.PREXBRL Presentation Linkbase Documents

*Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant undertakes to furnish supplementally a copy of any omitted exhibit or schedule upon request by the SEC.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ANGIODYNAMICS, INC.
Date:July 14, 2026By:/S/ HOWARD W. DONNELLY
Howard W. Donnelly,Chairman of the Board, Director

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Date:July 14, 2026/S/ HOWARD W. DONNELLY
Howard W. Donnelly,
Chairman of the Board, Director
Date:July 14, 2026/S/ JAMES C. CLEMMER
James C. Clemmer,
President, Chief Executive Officer(Principal Executive Officer)
Date:July 14, 2026/S/ STEPHEN A. TROWBRIDGE
Stephen A. Trowbridge,
Executive Vice President, Chief Financial Officer,(Principal Financial and Accounting Officer)
Date:July 14, 2026/S/ WESLEY E. JOHNSON, JR.
Wesley E. Johnson, Jr.,
Director
Date:July 14, 2026/S/ JAN S. REED
Jan S. Reed,
Director
Date:July 14, 2026/S/ EILEEN O. AUEN
Eileen O. Auen,
Director
Date:July 14, 2026/S/ KAREN A. LICITRA
Karen A. Licitra,
Director
Date:July 14, 2026/S/ MICHAEL E. TARNOFF
Michael E. Tarnoff,
Director
Date:July 14, 2026/S/ LORINDA A. BURGESS
Lorinda A. Burgess,
Director
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.